1.60
1.27%
0.02
시간 외 거래:
1.62
0.02
+1.25%
전일 마감가:
$1.58
열려 있는:
$1.58
하루 거래량:
65,563
Relative Volume:
0.55
시가총액:
$42.00M
수익:
-
순이익/손실:
$-14.14M
주가수익비율:
-2.00
EPS:
-0.8
순현금흐름:
$-12.64M
1주 성능:
-6.43%
1개월 성능:
-1.84%
6개월 성능:
-31.91%
1년 성능:
-55.18%
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Renaissance Technologies LLC Decreases Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201 - CGTLive™
Immix BiopharmaUS CAR-T trial progresses to dose expansion - Smartkarma
H.C. Wainwright confident in Immix stock growth with progress in NEXICART-2 CAR-T trial - Investing.com
Immix Biopharma’s (IMMX) “Buy” Rating Reiterated at HC Wainwright - Defense World
XTX Topco Ltd Sells 34,534 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort - GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 - StockTitan
Immix Biopharma stock hits 52-week low at $1.51 amid market challenges - Investing.com Australia
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
Immix Biopharma stock hits 52-week low at $1.74 amid market challenges - Investing.com Australia
Immix Biopharma Announces Dr. Raymond Comenzo, - GlobeNewswire
Immix Biopharma gains AL Amyloidosis expert for advisory board - Investing.com
Immix Biopharma gains AL Amyloidosis expert for advisory board By Investing.com - Investing.com Australia
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board - StockTitan
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update - MarketBeat
It would be worthwhile to take a closer look at Immix Biopharma Inc (IMMX) - US Post News
Its Stock Has Paid Off Big Time For Immix Biopharma Inc - SETE News
The Attractiveness of Investing In Immix Biopharma Inc (IMMX) is Growing - Knox Daily
Immix Biopharma Independent Director Acquires 2.6% More Stock - Yahoo Finance UK
Insider Spends US$52k Buying More Shares In Immix Biopharma - Simply Wall St
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy - Investing.com
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy By Investing.com - Investing.com Canada
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - GlobeNewswire
The markets will rise or fall with NVDA - RagingBull
Immix Biopharma director Jason Hsu buys $51,623 in company stock - Investing.com
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Immix Biopharma Inc’s latest rating changes from various analysts - Knox Daily
Q3 2024 Earnings Estimate for Immix Biopharma, Inc. Issued By HC Wainwright (NASDAQ:IMMX) - MarketBeat
HC Wainwright Weighs in on Immix Biopharma, Inc.’s Q3 2024 Earnings (NASDAQ:IMMX) - Defense World
Immix Biopharma, Inc. (NASDAQ:IMMX) Director Carey Ng Purchases 10,000 Shares of Stock - Defense World
Immix Biopharma, Inc. (NASDAQ:IMMX) Director Purchases $18,600.00 in Stock - MarketBeat
Immix Biopharma, Inc. to Post FY2024 Earnings of ($0.61) Per Share, Edison Inv. Res Forecasts (NASDAQ:IMMX) - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 7.5% in July - MarketBeat
What Makes Immix Biopharma (IMMX) a New Buy Stock - MSN
Immix Biopharma (NASDAQ:IMMX) Rating Reiterated by HC Wainwright - MarketBeat
HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World
FY2024 Earnings Forecast for Immix Biopharma, Inc. (NASDAQ:IMMX) Issued By Edison Inv. Res - Defense World
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024 - InvestorPlace
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Simply Wall St
Monitoring Immix Biopharma Inc (IMMX) after recent insider movements - Knox Daily
Jason Hsu Purchases 6,000 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) Stock - Defense World
Umoja Biopharma's In Situ CAR-T Therapy Cleared for US Trial in Hematologic Malignancies - CGTLive™
Immix Biopharma director Jason Hsu buys $19.5k in company shares - Investing.com
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immix Biopharma Inc 주식 (IMMX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Hsu Jason | Director |
Aug 22 '24 |
Buy |
2.25 |
8,100 |
18,233 |
845,300 |
Ng Carey | Director |
Aug 16 '24 |
Buy |
1.86 |
10,000 |
18,600 |
20,000 |
Hsu Jason | Director |
Jul 24 '24 |
Buy |
2.15 |
6,000 |
12,877 |
822,200 |
Hsu Jason | Director |
Jul 18 '24 |
Buy |
2.07 |
3,200 |
6,639 |
816,200 |
Rachman Ilya M | CEO and Chairman |
Jun 07 '24 |
Buy |
2.13 |
2,600 |
5,538 |
1,136,259 |
Morris Gabriel S | CFO |
Jun 07 '24 |
Buy |
2.12 |
2,500 |
5,298 |
285,834 |
Morris Gabriel S | CFO |
Jun 04 '24 |
Buy |
1.81 |
3,300 |
5,973 |
283,334 |
Rachman Ilya M | CEO and Chairman |
Jun 04 '24 |
Buy |
1.81 |
3,300 |
5,970 |
1,133,659 |
Morris Gabriel S | CFO |
May 14 '24 |
Buy |
2.23 |
4,500 |
10,042 |
85,816 |
Rachman Ilya M | CEO and Chairman |
May 14 '24 |
Buy |
2.25 |
4,300 |
9,660 |
912,000 |
자본화:
|
볼륨(24시간):